Search
Korro Bio Inc
KRROAdd to Watchlist
12.170USD
-1.600-11.62%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
175.52MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-11.62%
5 Days
-6.31%
1 Month
+4.82%
6 Months
+44.71%
Year to Date
+51.94%
1 Year
+1.93%
Key Figures
13.560Open
13.570High
243.86KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.69%Turnover Ratio
13.770Prev. Close
11.970Low
2.20MTurnover
LossP/E Static
1.47P/B
0.00%Div Yield TTM
-58.83%ROA
55.89052wk High
0.56Volume Ratio
-83.58MNet Profit
14.42MShares
-11.6804EPS TTM
3.02Beta
-87.78%ROE
5.20452wk Low
11.62%Amplitude
100.00%Gross Margin
175.52MMarket Cap
0.01Reward/Risk
5.67%Risk Rate
TradingKey Stock Score of Korro Bio Inc
Currency: USD Updated: 2026-06-25Key Insights
Korro Bio Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered undervalued, ranking 145 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.56.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Korro Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Korro Bio Inc Highlights
StrengthsRisks
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.39M.
Overvalued
The company’s latest PE is -1.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.84M shares, increasing 6.20% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 227.47K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.10.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
19.556
Target Price
+42.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Korro Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Korro Bio Inc Info
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Ticker SymbolKRRO
CompanyKorro Bio Inc
CEODr. Ram Aiyar, Ph.D.
Websitehttps://www.korrobio.com/
Related Instruments
+1.16%
+1.66%
+3.67%
+1.27%
+4.05%
+1.48%
+0.40%
+0.44%
-1.05%
-1.48%
+1.05%
+0.75%
+1.55%
+1.14%
-0.20%
0.00%
-0.53%
+4.24%
+0.73%
-0.54%Popular Instruments
52023.400
-1.300 (-0.00%)
29232.100
-222.900 (-0.76%)
7345.900
-20.900 (-0.28%)
15190.000
-561.000 (-3.56%)
69742.000
-1390.000 (-1.95%)
6242.400
-23.400 (-0.37%)
69.878
-1.466 (-2.06%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4030.580
+4.430 (+0.11%)
FAQs
What is the current price of Korro Bio Inc (KRRO)?
The current price of Korro Bio Inc (KRRO) is 12.17.
What is the symbol of Korro Bio Inc?
The ticker symbol of Korro Bio Inc is KRRO.
What is the 52-week high of Korro Bio Inc?
The 52-week high of Korro Bio Inc is 55.89.
What is the 52-week low of Korro Bio Inc?
The 52-week low of Korro Bio Inc is 5.20.
What is the market capitalization of Korro Bio Inc?
The market capitalization of Korro Bio Inc is 175.52M.
Is Korro Bio Inc (KRRO) currently rated as Buy, Hold, or Sell?
According to analysts, Korro Bio Inc (KRRO) has an overall rating of Buy, with a price target of 19.56.
What is the Earnings Per Share (EPS TTM) of Korro Bio Inc (KRRO)?
The Earnings Per Share (EPS TTM) of Korro Bio Inc (KRRO) is -12.48.
